- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
The goal of the Award is to recognize innovative nanomedicine-based solutions that could help physicians change the way diseases are treated and diagnosed, bringing significant benefits to patients.
The Award is open to companies, academic and private researchers across the globe. Nominated projects should represent new diagnostic and therapeutic approaches that address unmet medical needs, are not feasible without nanotechnology, are clearly distinct from standard approaches and have an explicit defined potential market.
Projects will be evaluated on the basis of being either a concept or a preclinical or clinical application in nanotherapeutics, diagnostic or regenerative medicine. Applications will be reviewed and assessed by a panel of highly-qualified pharma industry specialists with experience in R&D and commercial roles: Laurent Levy, Nanobiotix; Neil Desai, Celgene; Mike Eaton, consultant; Patrick Tricoli, Sanofi; Karen Zinkevich-Peotti, Ipsen and Thorsten Melcher, Johnson & Johnson Innovation.
The Award is supported by the EBD Group, the leading partnering firm for the global life science industry, and Nanobiotix, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The presentation of the Award will take place during the Nanomedicine Panel Discussion at BIO-Europe 2013 in Vienna, Austria, on 4th November 2013.
The winners will receive media coverage across Europe and gain visibility to EU decision makers from biotechnology, pharma, academia and finance. Winners will also benefit from a full registration (including partnering) for BIO-Europe 2013 and a 5 minute presentation slot at the Nanomedicine Panel Discussion during the event. In addition, the winning project will also be granted a 15 minute presentation slot during the CLINAM conference 2014 in Basel, Switzerland, along with 1 year's free ETPN membership and two days consultation by the members of the ETPN Translational Advisory Board.
Entries for nominations for the Award will be open from 6th June to 7th September 2013. The application form is available online: www.nanomedicine-award.com.
About VDI/VDE-Innovation + Technik GmbH
For High Tech to become a success story, VDI/VDE Innovation + Technik GmbH (VDI/VDE-IT) has been working hard for more than 25 years to be a reliable partner of industry and research and of the political community. With our fields of activity - Research Funding, Technology Politics and Innovation Management – we are covering the entire spectrum of the innovation process, from research through application all the way to the introduction and use of new technologies.
Our customers at home and abroad wish to implement innovations in the high-tech sector. Bringing our knowledge and experience to bear in important key technologies such as microsystems engineering, bio and nano technology and the multimedia, we assist our clients in translating their ideas into action, helping them to make their high-tech projects a success. With this objective in mind, our multidisciplinary team of over 100 experts in the natural and social sciences, engineers, and economists are continuously developing new ideas and methods, tailor-made to the personal needs of our customers.
VDI/VDE Innovation + Technik GmbH is a society of VDI GmbH and of VDE (Association for Electrical, Electronic & Information Technologies).
About ETP Nanomedicine - www.etp‐nanomedicine.eu
The European Technology Platform Nanomedicine was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.
About BIOEUROPE 2013 - www.ebdgroup.com/bioeurope
The 19th annual BIO-Europe event will be the largest biotechnology partnering conference held in Europe. Over 3,000 global decision makers from biotechnology, pharma and finance, representing upwards of 1,700 companies from over 50 countries, annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe will take place November 4–6, 2013 in Vienna, Austria.
Follow BIO-Europe 2013 on Twitter: twitter.com/ebdgroup (hashtag: #BEU13)
For more information, please click here
+49 30 310078-125
Copyright © AlphaGalileoIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Soft decoupling of organic molecules on metal June 23rd, 2016
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Soft decoupling of organic molecules on metal June 23rd, 2016
New nanoparticle technology developed to treat aggressive thyroid cancer: Platform designed to deliver nanotherapy effective in preclinical models of metastatic anaplastic thyroid cancer June 21st, 2016
FEI and University of Liverpool Announce QEMSCAN Research Initiative: University of Liverpool will utilize FEI’s QEMSCAN technology to gain a better insight into oil and gas reserves & potentially change the approach to evaluating them June 22nd, 2016
French Research Team Helps Extend MRI Detection of Diseases & Lower Health-Care Costs: CEA, INSERM and G2ELab Brings Grenoble Region’s Expertise In Advanced Medicine & Magnetism Applications to H2020 IDentIFY Project June 21st, 2016